A Phase 3 interventional study of Rotigotine and Placebo Patch in Idiopathic Parkinson's Disease, sponsored by UCB Pharma. Completed at 24 sites in China. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2018-04-04.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.
Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 8th largest by enrollment of the 42 interventional ones that give a count, is one of 8 that started in 2012, is one of 20 in phase 3, and was the 29th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
Browse Parkinson Disease studies →1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:
Eva Pharma
Ages 30+
rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 22 · Phase 4 8
First in 1999; this study’s year is marked. 8 started in 2012.
This study's enrollment of 346 is above the median of 40 across 3,355 interventional studies indexed under Parkinson Disease.
Median enrollment 123 across the 42 interventional studies. Of the 41 that completed or were terminated, 30 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
44 studies in Parkinson Disease by UCB S.A.: none open now, none under way, none of them phase 3. Of 44 finished, 29 (66%) have results posted.
Among the 44 studies in Parkinson Disease by UCB S.A., this one is the 9th largest by enrollment of the 34 interventional ones that give a count, is one of 8 that started in 2012, is one of 19 in phase 3, and was the 29th registered.
UCB S.A.’s Parkinson Disease studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing rotigotine in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 44 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study was to demonstrate that Rotigotine transdermal patch is efficacious in Chinese subjects with advanced-stage Idiopathic Parkinson's Disease as an adjuvant therapy.
The study included a maximum 4-week Screening Period, a maximum 7-week Titration Period for advanced-stage Parkinson's disease, 12-week Maintenance Period, a maximum 12-day De-escalation Period for advanced-stage Parkinson's Disease and 30-day Safety Follow-Up Period. The maximum study duration for an individual subject with advanced-stage Parkinson's disease was 27 weeks.
Inclusion Criteria:
Inclusion Criteria:
Exclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rotigotine, daily doses, treatment group
Drug: Rotigotine · Drug: L-dopa
Placebo, daily doses, placebo group
Drug: Placebo Patch · Drug: L-dopa
Transdermal Patch Content: 4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2) For advanced-stage Parkinson's Disease, subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 12 week maintenance period
Transdermal Patch Size: 20 cm\^2, 30 cm\^2, 40 cm\^2 Subjects randomized to placebo received matching placebo patches
Subject must be on a stable dose of L-dopa (either short-acting or sustained release \[in combination with benserazide or carbidopa\]) of at least 200 mg/day, administered in at least 2 intakes, for at least 28 days prior to Baseline.
Also known as: Levodopa
Absolute Change in Absolute Time Spent 'Off' From Baseline to the End of Double-blind Maintenance Period
A subject has been considered "off" when he/she began to lose the optimum effects of anti-Parkinson's medication. A negative mean indicates a reduction of the time off during the conduct of the study
Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 12)
Percentage of Responders From Baseline to the End of the Doubleblind Maintenance Period
A Responder is defined as a subject with an ≥ 30 % decrease in absolute time spent 'off'
Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 12)
Percent Change in Absolute Time Spent "Off" From Baseline to the End of Double-blind Maintenance Period
A subject has been considered "off" when he/she began to lose the optimum effects of anti-Parkinson's medication. Absolute time "off" is defined as the mean number of hours marked "off" during a 24-hour period from all valid daily diary cards.
Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 12)
Percent Change in Relative Time Spent "Off" From Baseline to the End of Double-blind Maintenance Period
A subject has been considered "off" when he/she began to lose the optimum effects of anti-Parkinson's medication. Relative time spent "off" will be calculated in two stages. Each valid daily diary will have an associated relative time "off" calculated as relative time "off" for day = 100\*\[total absolute time "off" for day/ absolute time awake for day\]. Relative time spent "off" is then calculated by averaging the daily relative time "off" for the valid days of that visit.
Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 12)
Change in Absolute Time Spent "on" From Baseline to the End of Double-blind Maintenance Period
A subject has been considered "on" when he/she felt the effects of L-dopa. The subject recorded the exact time of L-dopa intake and his/her status at the time of the L-dopa dose. In instances when the subject was 'off' when taking his/her L-dopa, he/she recorded the exact time their status changed to 'on'. Absolute time "on" is defined as the mean number of hours marked "on" during a 24-hour period from all valid daily diary cards.
Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 12)
Change in Relative Time Spent "on" From Baseline to the End of Double-blind Maintenance Period
A subject has been considered "on" when he/she felt the effects of L-dopa. The subject recorded the exact time of L-dopa intake and his/her status at the time of the L-dopa dose. In instances when the subject was "off" when taking his/her L-dopa, he/she recorded the exact time their status changed to "on". Relative time spent "on" will be calculated in two stages. Each valid daily diary will have an associated relative time "on" calculated as relative time "on" for day = 100\*\[total absolute time "on" for day/ absolute time awake for day\]. Relative time spent "on" is then calculated by averaging the daily relative time "on" for the valid days of that visit.
Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 12)
Percent Change in Absolute Time Spent "on" From Baseline to the End of Double-blind Maintenance Period
A subject has been considered "on" when he/she felt the effects of L-dopa. The subject recorded the exact time of L-dopa intake and his/her status at the time of the L-dopa dose. In instances when the subject was 'off' when taking his/her L-dopa, he/she recorded the exact time their status changed to 'on'. Note for percent change calculations: when absolute time at Baseline was 0 hours, the absolute Baseline value was assumed to be 1 minute for calculation purposes.
Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 12)
Percent Change in Relative Time Spent "on" From Baseline to the End of Double-blind Maintenance Period
A subject has been considered "on" when he/she felt the effects of L-dopa. The subject recorded the exact time of L-dopa intake and his/her status at the time of the L-dopa dose. In instances when the subject was "off" when taking his/her L-dopa, he/she recorded the exact time their status changed to "on". Note for percent change calculations: when relative time at Baseline was 0%, the relative Baseline value was assumed to be 0.1 for calculation purposes. Relative time spent "on" will be calculated in two stages. Each valid daily diary will have an associated relative time "on" calculated as relative time "on" for day = 100\*\[total absolute time "on" for day/ absolute time awake for day\]. Relative time spent "on" is then calculated by averaging the daily relative time "on" for the valid days of that visit.
Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 12)
Change in the Number of "Off" Periods From Baseline to the End of Double-blind Maintenance Period
A subject has been considered "off" when he/she began to lose the optimum effects of anti-Parkinson's medication.
Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 12)
Change in Status of the Subject (on) After Wake-up With Troublesome Dyskinesia From Baseline to the End of Double-blind Maintenance Period
A subject has been considered "on" when he/she felt the effects of L-dopa. The subject recorded the exact time of L-dopa intake and his/her status at the time of the L-dopa dose. In instances when the subject was 'off' when taking his/her L-dopa, he/she recorded the exact time their status changed to 'on'. The percentage of days from Baseline to the end of the double-blind Maintenance Period in which the subject woke in the "on with troublesome dyskinesia" state is presented below.
Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 12)
Change in Status of the Subject (on) After Wake-up Without Troublesome Dyskinesia From Baseline to the End of Double-blind Maintenance Period
A subject has been considered "on" when he/she felt the effects of L-dopa. The subject recorded the exact time of L-dopa intake and his/her status at the time of the L-dopa dose. In instances when the subject was 'off' when taking his/her L-dopa, he/she recorded the exact time their status changed to 'on'. The percentage of days from Baseline to the end of the double-blind Maintenance Period in which the subject woke in the "on without troublesome dyskinesia" state is presented below.
Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 12)
Change in Status of the Subject (Off) After Wake-up From Baseline to the End of Double-blind Maintenance Period
A subject has been considered "off" when he/she began to lose the optimum effects of anti-Parkinson's medication. The percentage of days from Baseline to the end of the double-blind Maintenance Period in which the subject woke in the "off" state is presented below.
Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 12)
Change in Unified Parkinson's Disease Rating Scale (UPDRS Part III Motor Examination) During "on" Periods From Baseline to the End of Double-blind Maintenance Period
The UPDRS Part III (motor subscale) assessment consists of 27 questions, measured on a 5-Point scale (0 to 4). The sum score is calculated as sum of these 27 individual questions. This score ranges from 0 to 108, higher scores denote greater disability. A subject has been considered "on" when he/she felt the effects of L-dopa. The subject recorded the exact time of L-dopa intake and his/her status at the time of the L-dopa dose. In instances when the subject was 'off' when taking his/her L-dopa, he/she recorded the exact time their status changed to 'on'.
Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 12)
This multicenter, randomized, double-blind, parallel-group, placebo-controlled study started recruiting in August 2012.
| Milestone | Placebo | Rotigotine |
|---|---|---|
| Started | 172 | 174 |
| Completed | 151 | 160 |
| Not completed | 21 | 14 |
| Withdrew: Adverse event | 7 | 8 |
| Withdrew: Lack of efficacy | 2 | 0 |
| Withdrew: Withdrawal by subject | 10 | 6 |
| Withdrew: Compliance is not well | 1 | 0 |
| Withdrew: Inclusion criteria deviation | 1 | 0 |
A subject has been considered "off" when he/she began to lose the optimum effects of anti-Parkinson's medication. A negative mean indicates a reduction of the time off during the conduct of the study
| hours | Full Analysis Set (Placebo Treated Subjects) | Full Analysis Set (Rotigotine Treated Subjects) |
|---|---|---|
| Absolute Change in Absolute Time Spent 'Off' From Baseline to the End of Double-blind Maintenance Period | -1.13 ± 3.20 | -2.36 ± 2.83 |
A Responder is defined as a subject with an ≥ 30 % decrease in absolute time spent 'off'
| percentage of participants | Full Analysis Set (Placebo Treated Subjects) | Full Analysis Set (Rotigotine Treated Subjects) |
|---|---|---|
| Percentage of Responders From Baseline to the End of the Doubleblind Maintenance Period | 36.9 | 48.8 |
A subject has been considered "off" when he/she began to lose the optimum effects of anti-Parkinson's medication. Absolute time "off" is defined as the mean number of hours marked "off" during a 24-hour period from all valid daily diary cards.
| percent change | Full Analysis Set (Placebo Treated Subjects) | Full Analysis Set (Rotigotine Treated Subjects) |
|---|---|---|
| Percent Change in Absolute Time Spent "Off" From Baseline to the End of Double-blind Maintenance Period | -15.0 ± 56.56 | -36.03 ± 43.03 |
A subject has been considered "off" when he/she began to lose the optimum effects of anti-Parkinson's medication. Relative time spent "off" will be calculated in two stages. Each valid daily diary will have an associated relative time "off" calculated as relative time "off" for day = 100\*\[total absolute time "off" for day/ absolute time awake for day\]. Relative time spent "off" is then calculated by averaging the daily relative time "off" for the valid days of that visit.
| percent change | Full Analysis Set (Placebo Treated Subjects) | Full Analysis Set (Rotigotine Treated Subjects) |
|---|---|---|
| Percent Change in Relative Time Spent "Off" From Baseline to the End of Double-blind Maintenance Period | -14.86 ± 53.26 | -34.97 ± 43.87 |
A subject has been considered "on" when he/she felt the effects of L-dopa. The subject recorded the exact time of L-dopa intake and his/her status at the time of the L-dopa dose. In instances when the subject was 'off' when taking his/her L-dopa, he/she recorded the exact time their status changed to 'on'. Absolute time "on" is defined as the mean number of hours marked "on" during a 24-hour period from all valid daily diary cards.
| hours | Full Analysis Set (Placebo Treated Subjects) | Full Analysis Set (Rotigotine Treated Subjects) |
|---|---|---|
| Change in Absolute Time Spent "on" From Baseline to the End of Double-blind Maintenance Period | 0.94 ± 3.08 | 2.05 ± 2.98 |
A subject has been considered "on" when he/she felt the effects of L-dopa. The subject recorded the exact time of L-dopa intake and his/her status at the time of the L-dopa dose. In instances when the subject was "off" when taking his/her L-dopa, he/she recorded the exact time their status changed to "on". Relative time spent "on" will be calculated in two stages. Each valid daily diary will have an associated relative time "on" calculated as relative time "on" for day = 100\*\[total absolute time "on" for day/ absolute time awake for day\]. Relative time spent "on" is then calculated by averaging the daily relative time "on" for the valid days of that visit.
| hours | Full Analysis Set (Placebo Treated Subjects) | Full Analysis Set (Rotigotine Treated Subjects) |
|---|---|---|
| Change in Relative Time Spent "on" From Baseline to the End of Double-blind Maintenance Period | 6.78 ± 19.61 | 14.49 ± 18.70 |
A subject has been considered "on" when he/she felt the effects of L-dopa. The subject recorded the exact time of L-dopa intake and his/her status at the time of the L-dopa dose. In instances when the subject was 'off' when taking his/her L-dopa, he/she recorded the exact time their status changed to 'on'. Note for percent change calculations: when absolute time at Baseline was 0 hours, the absolute Baseline value was assumed to be 1 minute for calculation purposes.
| percent change | Full Analysis Set (Placebo Treated Subjects) | Full Analysis Set (Rotigotine Treated Subjects) |
|---|---|---|
| Percent Change in Absolute Time Spent "on" From Baseline to the End of Double-blind Maintenance Period | 13.53 ± 42.74 | 368.55 ± 4446.55 |
A subject has been considered "on" when he/she felt the effects of L-dopa. The subject recorded the exact time of L-dopa intake and his/her status at the time of the L-dopa dose. In instances when the subject was "off" when taking his/her L-dopa, he/she recorded the exact time their status changed to "on". Note for percent change calculations: when relative time at Baseline was 0%, the relative Baseline value was assumed to be 0.1 for calculation purposes. Relative time spent "on" will be calculated in two stages. Each valid daily diary will have an associated relative time "on" calculated as relative time "on" for day = 100\*\[total absolute time "on" for day/ absolute time awake for day\]. Relative time spent "on" is then calculated by averaging the daily relative time "on" for the valid days of that visit.
| percent change | Full Analysis Set (Placebo Treated Subjects) | Full Analysis Set (Rotigotine Treated Subjects) |
|---|---|---|
| Percent Change in Relative Time Spent "on" From Baseline to the End of Double-blind Maintenance Period | 14.99 ± 42.60 | 616.80 ± 7667.58 |
A subject has been considered "off" when he/she began to lose the optimum effects of anti-Parkinson's medication.
| Number of 'off' Periods | Full Analysis Set (Placebo Treated Subjects) | Full Analysis Set (Rotigotine Treated Subjects) |
|---|---|---|
| Change in the Number of "Off" Periods From Baseline to the End of Double-blind Maintenance Period | -0.61 ± 1.59 | -0.89 ± 1.32 |
A subject has been considered "on" when he/she felt the effects of L-dopa. The subject recorded the exact time of L-dopa intake and his/her status at the time of the L-dopa dose. In instances when the subject was 'off' when taking his/her L-dopa, he/she recorded the exact time their status changed to 'on'. The percentage of days from Baseline to the end of the double-blind Maintenance Period in which the subject woke in the "on with troublesome dyskinesia" state is presented below.
| percentage of days | Full Analysis Set (Placebo Treated Subjects) | Full Analysis Set (Rotigotine Treated Subjects) |
|---|---|---|
| Change in Status of the Subject (on) After Wake-up With Troublesome Dyskinesia From Baseline to the End of Double-blind Maintenance Period | 2.42 ± 21.70 | 1.24 ± 16.90 |
A subject has been considered "on" when he/she felt the effects of L-dopa. The subject recorded the exact time of L-dopa intake and his/her status at the time of the L-dopa dose. In instances when the subject was 'off' when taking his/her L-dopa, he/she recorded the exact time their status changed to 'on'. The percentage of days from Baseline to the end of the double-blind Maintenance Period in which the subject woke in the "on without troublesome dyskinesia" state is presented below.
| percentage of days | Full Analysis Set (Placebo Treated Subjects) | Full Analysis Set (Rotigotine Treated Subjects) |
|---|---|---|
| Change in Status of the Subject (on) After Wake-up Without Troublesome Dyskinesia From Baseline to the End of Double-blind Maintenance Period | 7.92 ± 43.29 | 22.55 ± 45.41 |
A subject has been considered "off" when he/she began to lose the optimum effects of anti-Parkinson's medication. The percentage of days from Baseline to the end of the double-blind Maintenance Period in which the subject woke in the "off" state is presented below.
| percentage of days | Full Analysis Set (Placebo Treated Subjects) | Full Analysis Set (Rotigotine Treated Subjects) |
|---|---|---|
| Change in Status of the Subject (Off) After Wake-up From Baseline to the End of Double-blind Maintenance Period | -10.34 ± 47.81 | -21.14 ± 48.49 |
The UPDRS Part III (motor subscale) assessment consists of 27 questions, measured on a 5-Point scale (0 to 4). The sum score is calculated as sum of these 27 individual questions. This score ranges from 0 to 108, higher scores denote greater disability. A subject has been considered "on" when he/she felt the effects of L-dopa. The subject recorded the exact time of L-dopa intake and his/her status at the time of the L-dopa dose. In instances when the subject was 'off' when taking his/her L-dopa, he/she recorded the exact time their status changed to 'on'.
| units on a scale | Full Analysis Set (Placebo Treated Subjects) | Full Analysis Set (Rotigotine Treated Subjects) |
|---|---|---|
| Change in Unified Parkinson's Disease Rating Scale (UPDRS Part III Motor Examination) During "on" Periods From Baseline to the End of Double-blind Maintenance Period | -3.6 ± 9.8 | -10.4 ± 10.4 |
Collected over Treatment-emergent Adverse Events (TEAE) were collected during the study, which began in August 2012 and concluded in October 2014.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 6/172 (3.5%) | 24/172 (14%) |
| Rotigotine | — | 6/174 (3.4%) | 54/174 (31%) |
| Event | Placebo | Rotigotine |
|---|---|---|
| SyncopeNervous system disorders | 0/172 | 2/174 |
| Mitral valve prolapseCardiac disorders | 1/172 | 0/174 |
| Atrial fibrillationCardiac disorders | 1/172 | 0/174 |
| Intestinal obstructionGastrointestinal disorders | 1/172 | 0/174 |
| Parkinson's diseaseNervous system disorders | 1/172 | 0/174 |
| Urinary retentionRenal and urinary disorders | 1/172 | 0/174 |
| VasculitisVascular disorders | 1/172 | 0/174 |
| Inguinal herniaGastrointestinal disorders | 0/172 | 1/174 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/172 | 1/174 |
| Skin infectionInfections and infestations | 0/172 | 1/174 |
| Event | Placebo | Rotigotine |
|---|---|---|
| DizzinessNervous system disorders | 7/172 | 19/174 |
| NauseaGastrointestinal disorders | 2/172 | 16/174 |
| PruritusSkin and subcutaneous tissue disorders | 10/172 | 14/174 |
| DyskinesiaNervous system disorders | 7/172 | 11/174 |
Baseline Characteristics refers to to the Safety Set (SS), consisting of all randomized subjects who received at least 1 dose of study medication.
| Age, Categorical(Participants) | Placebo | Rotigotine | Total Title |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 96 | 111 | 207 |
| >=65 years | 76 | 63 | 139 |
| Age, Continuous(years) | Placebo | Rotigotine | Total Title |
|---|---|---|---|
| mean (standard deviation) | 62.8 ± 9.1 | 61.7 ± 8.8 | 62.2 ± 8.9 |
| Sex: Female, Male(Participants) | Placebo | Rotigotine | Total Title |
|---|---|---|---|
| Female | 62 | 81 | 143 |
| Male | 110 | 93 | 203 |
| Weight(kg) | Placebo | Rotigotine | Total Title |
|---|---|---|---|
| Mean | 61.83 ± 10.18 | 60.38 ± 10.15 | 61.10 ± 10.18 |
The record gives a start of Jul 2012, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2016, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine